CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, will be featured in a Spotlight poster discussion session at the San Antonio Breast Cancer Symposium taking place December 4-8 in San Antonio. The data show that SY-1365 has dose-dependent inhibitory activity in hormone receptor-positive breast cancer cell lines that are resistant to treatment with CDK4/6 inhibitors.
The abstract for this presentation is now available online on the SABCS website at https://www.sabcs.org.
Details on the presentation are as follows:
Presentation Title: Inhibition of CDK7 overcomes resistance to CDK4/6
inhibitors in hormone receptor-positive breast cancer cells
Session
Date & Time: Friday, December 7, 7:00-9:00 a.m. CT (8:00-10:00 a.m. ET)
Session
Title: Spotlight Session 7: Lobular Breast Cancer
Presenter: Dr.
Cristina Guarducci, Dana Farber Cancer Institute
Abstract Number:
1008
Program Number: PD7-12
Location: Stars at Night Ballroom,
Henry B. Gonzalez Convention Center
About Syros Pharmaceuticals
Syros is pioneering the
understanding of the non-coding regulatory region of the genome to
advance a new wave of medicines that control the expression of genes.
Syros has built a proprietary platform that is designed to
systematically and efficiently analyze this unexploited region of DNA to
identify and drug novel targets linked to genomically defined patient
populations. Because gene expression is fundamental to the function of
all cells, Syros’ gene control platform has broad potential to create
medicines that achieve profound and durable benefit across a range of
diseases. Syros is currently focused on cancer and monogenic diseases
and is advancing a growing pipeline of gene control medicines. Syros’
lead drug candidates are SY-1425, a selective RARα agonist in a Phase 2
clinical trial for genomically defined subsets of patients with acute
myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective
CDK7 inhibitor in a Phase 1 clinical trial for patients with ovarian and
breast cancers. Syros is also developing a deep preclinical and
discovery pipeline, including SY-5609, an oral CDK7 inhibitor, as well
as programs in immuno-oncology and sickle cell disease. Led by a team
with deep experience in drug discovery, development and
commercialization, Syros is located in Cambridge, Mass.
Cautionary Note Regarding Forward-Looking Statements
This
press release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995, including without
limitation statements regarding the potential benefits of CDK7
inhibition and of SY-1365 in HR+ breast cancer; and the benefits of
Syros’ gene control platform. The words ‘‘anticipate,’’ ‘‘believe,’’
‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’
‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’
‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements
contain these identifying words. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
these forward-looking statements as a result of various important
factors, including Syros’ ability to: advance the development of its
programs, including SY-1365, under the timelines it projects in current
and future clinical trials; demonstrate in any current and future
clinical trials the requisite safety, efficacy and combinability of its
drug candidates; replicate scientific and non-clinical data in clinical
trials; obtain and maintain patent protection for its drug candidates
and the freedom to operate under third party intellectual property;
obtain and maintain necessary regulatory approvals; identify, enter into
and maintain collaboration agreements with third parties; manage
competition; manage expenses; raise the substantial additional capital
needed to achieve its business objectives; attract and retain qualified
personnel; and successfully execute on its business strategies; risks
described under the caption “Risk Factors” in Syros’ Annual Report on
Form 10-K for the year ended December 31, 2017, as updated in its
Quarterly Reports on Form 10-Q for the quarters ended March 31, June 30
and September 30, 2018, each of which is on file with the Securities and
Exchange Commission; and risks described in other filings that Syros
makes with the Securities and Exchange Commission in the future. Any
forward-looking statements contained in this press release speak only as
of the date hereof, and Syros expressly disclaims any obligation to
update any forward-looking statements, whether because of new
information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181109005529/en/
Media Contact:
Syros Pharmaceuticals
Naomi Aoki,
617-283-4298
naoki@syros.com
or
Investor
Contact:
Stern Investor Relations, Inc.
Hannah
Deresiewicz, 212-362-1200
hannahd@sternir.com
Source: Syros Pharmaceuticals
Released November 9, 2018